{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-018764","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.837653+00:00","generated_at":"2026-06-05T19:24:44.435679+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Athira Pharma FY2023 net loss $117.7M; LIFT-AD enrollment complete; data H2 2024","bullets":["Net loss $117.7M ($3.09/sh) vs $95.6M ($2.53/sh) in FY2022; R&D spend rose to $93.8M.","Cash and investments $147.4M as of Dec 31, 2023, down from $245.2M at end of 2022.","Phase 2/3 LIFT-AD trial (fosgonimeton) enrollment completed (~315 pts); topline data expected H2 2024.","First-in-human study of ATH-1105 for ALS on track to initiate in H1 2024.","Adopted 2024 Inducement Plan reserving 750,000 shares; appointed COO/Chief Dev Officer and Chief People Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-018764","json":"https://secwatch.observer/filing/0000950170-24-018764.json","markdown":"https://secwatch.observer/filing/0000950170-24-018764.md","text":"https://secwatch.observer/filing/0000950170-24-018764.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000095017024018764/0000950170-24-018764-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000095017024018764/atha-20240221.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T19:24:44.435679+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c60e99ebda636bffdcb9d74df717d0454fe718dd","claim":"LeonaBio, Inc. reported financial results for the year ended December 31, 2023.","evidence_excerpt":"On February 22, 2024, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1620463/000095017024018764/0000950170-24-018764-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}